Clinical Trial

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2022-09-22; most recent amendment 2026-04-22.
Status change: Not Yet Recruiting → Recruiting 2022-11-14
Trial Details
NCT Number NCT05557045
Lead Sponsor Jazz Pharmaceuticals
Conditions Advanced Cancer, Metastatic Cancer, Solid Tumor
Enrollment 332 participants
Start Date 2022-10-10
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23